| INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer in the world. 1 SCCHN occurs predominantly in patients over 50 years old, and similar to most malignancies aging is a pervasive risk factor. 2 Epidemiologic studies show an increasing incidence of SCCHN in patients under 40 years of age, especially for SCC of the oral tongue (SCCOT). [3] [4] [5] As these patients have not encountered extensive exposure to alcohol/tobacco, the main risk factors for SCCHN, tumor induction in young patients are likely to be etiologically distinct. 5 Numerous efforts have been made to identify differences in pathogenesis between the two age-groups, but no consensus has yet been reached. 5 More recent next-generation sequencing techniques indicate that the genomic profiles and mutations in driver genes are very similar between young and older SCCOT patients, 6 suggesting similar mechanisms of tumorigenesis.
The prognosis of SCCHN in young patients is controversial.
Many studies have not shown any significant difference in prognosis between young and older patients, whereas some have suggested that young patients have worse outcomes and thus need more aggressive approaches to improve locoregional control and survival. 7, 8 Other studies in turn have demonstrated that young patients have a better overall prognosis than older patients. 3, 9 Our own results from SCCOT showed recurrences more frequently in young compared to old patients. 10 To gain further insight into SCCOT in young patients and enable identification of those with poor prognosis and in need of more individualized treatment, we used next-generation sequencing to investigate both gene expression profiles and genomic features in tumors from young and elderly patients and evaluated the correlation between molecular pattern and clinical outcome.
| MATERIALS AND METHODS

| Patients and samples
In order to provide a clear-cut distinction for age classification, we considered patients aged ≤40 years at diagnosis as young and 
| DNA/RNA isolation
Biopsies were fresh frozen in liquid nitrogen and stored at −80°C.
AllPrep DNA/RNA/miRNA Universal Kit (Qiagen, Hilden, Germany) was used to isolate DNA and RNA. For the blood samples, fractions of plasma, buffy coat, and red blood cells were prepared and stored at −80°C. Buffy coat DNA was extracted using the illustra Nucleon Genomic DNA Extraction kit (GE Healthcare, UK). Quantity and purity of DNA/RNA was measured using a NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE, USA Somatic copy number variation (CNV) analysis was conducted using the EXCAVATOR2 tool. 14 Whenever available, paired blood sample was used as germline reference (paired mode). Otherwise, the matched tumor-free tongue sample (paired mode) was used.
Log2R was denoted as the log-transformed copy number ratio between tumor and control samples. A segmentation log2R value 0 indicates normal diploid status. To measure CNV burden, fraction of copy number-altered genome (FCA) was calculated by dividing the number of bases in segments with mean log2R >0.2 or <−0.2 by the number of bases in all segments. 15 Germline single nucleotide polymorphisms (SNPs) and insertions/ deletions (indels) were identified using GATK HaplotypeCaller (version 4.0). 16 Variants with at least 5 counts of the alternate allele and an alternative allele frequency of at least 20% were identified. Of these, we filtered out variants with >0.05% allele frequency in the databases. Based on the latest curated list of 152 cancer predisposition genes, 17 we further selected for potential cancer predisposing truncation and missense variants.
| The cancer genome atlas (TCGA) data collection and analysis
TCGA has studied 528 patients with SCCHN, including 133 patients with SCCOT. Thirteen SCCOT patients were young (19-40 years), and 102 were elderly (50-90 years). Clinical information, somatic SNV, and CNV data (in terms of FCA) were downloaded using cBioPortal. 15 In the TCGA data, overall survival time was unknown for one young SCCOT patient and CNV data were not available for three elderly patients. The effect of CNV on overall survival was estimated by Kaplan-Meier and correlations between CNV and clinical outcome in young and elderly patients were determined by Fisher's exact test using IBM SPSS statistics 23.
P < 0.05 was considered significant.
| RESULTS
| Overview of transcriptomes in tumor and tumor-free tongue samples
RNA-Seq data were analyzed to study gene expression profiles (both coding and non-coding RNAs) in tumor and matched tumor-free tongue samples. Principal component analysis (PCA) clearly separated tumor-free and tumor samples ( Figure 1 ). As SCCHN genetic profiles and prognosis differ according to HPV status, 18 we investigated HPV infection using HPVDetector. In keeping with previous reports from SCCOT, 19 no sign of HPV was seen. Comparing tumors between young and elderly patients, no age-specific transcriptional profiles were identified. (Table 2) . Gene ontology analysis showed that these genes were enriched in chromatin organization and negative regulation of cell proliferation. Compared to previous reports and the elderly patients studied here, no driving events were specific for the four young patients, or related to clinical outcome. 1  p35  Female  24  Non-smoker  2  T2N0M0  13  Dead  T, TF   2  p82  Female  19  Former Smoker   b   1  T4aN0M0  18  Dead  T, BL   3  p98  Male  31  Non-smoker  3  T2N0M0  62  Alive  T, TF,BL   4  p111  Female  31  Smoker  2  T1N0M0  53  Alive  T, TF,BL   5  p119  Male  67  Non-smoker  2  T2N0M0  47  Alive  T, TF,BL   6  p124  Male  55  Unknown  1, 3  T4N2bM0  3  Dead  T, TF,BL   7  p137  Female  71  Non-smoker  2  T2N0M0  38  Alive  T, TF,BL   8  p149  Female  69  Former smoker   c   2  T1N0M0  18  Dead   d   T, TF,BL   9  p154  Female  42  Unknown  4  T1N1M0  28 Overall, gene expression profiles in tumors from young patients (patient ID in red) were similar to those from older patients
| Somatic single nucleotide variations (SNVs)
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| Somatic copy number variations (CNVs)
Based on segmented WES data by EXCAVATOR2, broad level CNVs (length >50% of a chromosome arm) were found in the tumor samples of two young patients, p35 and p82, including loss of 3p and 8p and gain of 3q, 5p, and 8q, typical for SCCHN, 18 whereas no broad level CNV was found in the other two young patients (p98 and p111) (Figure 2 ). CNV burden, calculated as the fraction of copy number-altered genome (FCA), showed that only 0.4% and 0.2% of the tumor genomes from p98 and p111 showed changes in copy number, respectively. All tumor samples from elderly patients showed broad level CNVs (Figure 2 ). CNV burden (measured as FCA) in tumor samples is shown in Table 2 .
| Correlation between CNV and clinical outcome
High levels of CNV were seen in tumors from the two young patients with poor outcome (p35 and p82), whereas low tumor CNV burdens were present in the two patients with better outcome (p98 and p111) ( Table 2 aged ≥50 years were considered elderly, and those ≤40 years were classified as young). Based on the estimate that 4.8% of the human genome can be variable, 21 an FCA value >0.05 (5% of the copy number-profiled genome) was defined as high CNV and ≤0.05 as low CNV. First, we looked at the whole group of SCCHN, showing no significant correlations between CNV burden and overall survival using log-rank test (Figure 3, upper panel) .
When looking at SCCOT only and combining SCCOT data from TCGA with our SCCOT data (ALL-SCCOT), significantly better overall survival was seen in young SCCOT patients with low CNV (n = 5) compared to young patients with high CNV (n = 11) (P = 0.044) (Figure 3, lower panel) . Even if the total number of young patients analyzed is low, no young patient with low-CNV levels had died, whereas for elderly patients, no significant difference in overall survival was seen between patients with low-and high-CNV burden. Considering patients alive without tumor after 2 years as having better clinical outcome, we found that low CNV correlated with better clinical outcome in young (P = 0.017, Fisher's exact test), but not elderly patients with SCCOT (P = 0.595).
| Pathogenic germline variants
No blood sample was available from one young patient (p35), and thus, germline variant calling was conducted for nine blood samples.
Five pathogenic germline variants were identified in four patients (Table 2) . One young patient (p98) harbored missense variants in ERCC2 and EXT1, and a missense variant in BRCA1 was detected in another young patient (p111). Patient 154 (aged 42 years) contained a missense variant in RET and a truncated variant in RAD51C was identified in patient 137, the oldest patient in this study. Of these, EXT1 has been reported as a tumor suppressor 22 and RET as a proto-oncogene. 23 The other three genes with germline variants are tumor suppressor genes involved in various DNA repair pathways and the most frequently identified germline variants across different cancer types. 
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Overall survival analysis by Kaplan-Meier method. Patients were divided into groups according to age. Overall survival analysis was performed using Kaplan-Meier method. Log-rank P values are shown in the plots. The red line represents patients with high-CNV burden and the blue line patients with low-CNV burden. According to TCGA data (TCGA-SCCHN), there was no significant correlation between overall survival and CNV burden for the whole group of patients with SCCHN. The number of young patients (19-40 y) with low or high CNV being 3 and 18, respectively. Combining TCGA on SCCOT with our data (ALL-SCCOT), the overall survival rate in young patients with low-CNV (n = 5) was significantly higher than that in young patients with high-CNV (n = 11) (log-rank test P = 0.044)
